Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study
Open Access
- 1 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 16 (9), 1567-1574
- https://doi.org/10.1002/ibd.21193
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic indexClinical Journal of Gastroenterology, 2008
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2004
- Dysbiosis in inflammatory bowel diseaseGut, 2004
- Oral Mesalamine (Asacol) for Mildly to Moderately Active Ulcerative ColitisAnnals of Internal Medicine, 1991
- Mesalazine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Chronic Inflammatory Bowel DiseaseDrugs, 1989
- Delayed‐release mesalazine (5‐aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.British Journal of Clinical Pharmacology, 1988
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.Gut, 1987
- Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.Gut, 1987
- Variation Between Observers in Describing Mucosal Appearances in ProctocolitisBMJ, 1964